Search Results

Michel Ducreux

Adding the oral drug capecitabine to a regimen of bevacizumab plus irinotecan was as effective as adding infusions of 5FU/folinic acid for patients who had metastatic colorectal cancer in a phase II study presented to the World Congress on Gastrointestinal Cancer in Barcelona (24-27 June, 2009; Abstract: 0-0013). Michel Ducreux, Head of the Gastrointestinal Service at the Institut Gustave Roussy in Villejuif, Paris, discussed the new evidence and its clinical implications with Peter Goodwin.